Added to YB: 2026-01-20
Pitch date: 2026-01-17
MDNAF [neutral]
Medicenna Therapeutics Corp.
-9.47%
current return
Author Info
Penny Queen focuses on undiscovered value, deep dives, swing trades and special situations. Sign up for the newsletter.
Company Info
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases.
Market Cap
CAD 79.2M
Pitch Price
CAD 0.95
Price Target
N/A
Dividend
N/A
EV/EBITDA
-2.93
P/E
-5.54
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Penny Queen 2026 Portfolio Update: Medicenna Therapeutics Corp.
MDNAF (holding update): 50% ORR in expansion cohorts, 42% in checkpoint inhibitor failures - monotherapy results without Keytruda. Multiple value paths: salvage therapy, combination play, neoadjuvant. Standalone utility more valuable for M&A than just Keytruda extender. Runway only to Q3 2025.
Read full article (1 min)